BT-PROTAC

BT-PROTAC (48 h) exhibits low cytotoxicity when acting alone on T47D breast cancer cells, with an IC₅₀ of 1761.0 nM; however, its cytotoxicity is restored after pre-incubation with BODIPY-TZ, and the IC₅₀ decreases to 407.0 nM^[1].
BT-PROTAC (48 h) exhibits low cytotoxicity when acting alone on MDA-MB-231 breast cancer cells, with an IC₅₀ of 652.2 nM; however, its cytotoxicity is restored after pre-incubation with BODIPY-TZ, and the IC₅₀ decreases to 326.5 nM^[1].
BT-PROTAC (48 h) exhibits low cytotoxicity when applied alone to MCF-7 breast cancer cells, with an IC₅₀ of 1319.0 nM; however, its cytotoxicity is restored after pre-incubation with BODIPY-TZ, and the IC₅₀ decreases to 263.6 nM^[1].
BT-PROTAC (0-2.0 μM; 48 h) alone does not degrade BRD4 or BRD3 in T47D, MB-231, and MCF-7 breast cancer cells even at concentrations as high as 2.0 μM, but achieves degradation of BRD4 and BRD3 via the ubiquitin-proteasome system after pre-incubation with BODIPY-TZ^[1].
After activation by BODIPY-TZ, BT-PROTAC (48 h) inhibits c-Myc expression and activates caspase-3 in T47D, MDA-MB-231 and MCF-7 breast cancer cells^[1].

MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.